Ocular Therapeutix Expands Its Board of Directors with the Appointment of Renowned Retinal Specialist Jeffrey S. Heier, M.D.

BEDFORD, Mass.–(BUSINESS WIRE)–Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Jeffrey S. Heier, M.D., a prominent retinal specialist, has been elected to Ocular’s Board of Directors. Dr. Heier is a leading retinal clinical researcher of new treatments for diseases of the back of the eye, including macular degeneration, diabetic macular edem


Complicated cases bring out the best in femtosecond laser cataract surgery

BARCELONA — While most surgeons are still using femtosecond laser-assisted cataract surgery only in standard cases, in which no significant difference from classic phaco has yet been demonstrated, the true advantages are in a wide range of complicated cases, according to José L. Güell, MD.At a symposium on femtosecond laser cataract during the European Society of Cataract and Refractive Surgeons meeting, he showed examples of several situations in which laser makes the difference for the surgeon and the eye he or she is operating on.

Pupil expansion device gently deals with small pupil problems during cataract surgery

BARCELONA — A new pupil expansion device allows a safer, gentler approach to intraoperative floppy iris syndrome, pseudoexfoliation and small pupils during surgery.The I-Ring pupil expander (Beaver Visitec) is made of soft polyurethane, as opposed to the stiffer polypropylene more commonly used in pupil expansion devices. It is preloaded in an inserter and injected through the phaco incision.